Sequent Scientific Ltd.

Financial

	Sequent Scientific	Gufic Biosciences	Panacea Biotec
Operational Metrics
Pharmaceutical Sector
R&D as a % of Total Sales	0.0	0.83 %	5.51 %
Financials
5 yr Average ROE	1.28 %	25.05 %	17.16 %
5yr average Equity Multiplier	2.12	2.22	1.61
5yr Average Asset Turnover Ratio	0.92	1.05	0.4
5yr Avg Net Profit Margin	0.94 %	10.9 %	19.26 %
Price to Book	5.27	6.29	4.01
P/E	307.69	44.08	0.0
5yr Avg Cash Conversion Cycle	55.84 Days	26.94 Days	-102.87 Days
Inventory Days	76.26 Days	66.86 Days	109.97 Days
Days Receivable	87.51 Days	128.09 Days	37.7 Days
Days Payable	117.98 Days	163.91 Days	294.14 Days
5yr Average Interest Coverage Ratio	2.31	13.1	2.9
5yr Avg ROCE	7.29 %	27.25 %	-1.68 %
5yr Avg Operating Profit Margin	8.58 %	18.45 %	-1.99 %
5 yr average Debt to Equity	0.5	0.51	0.05
5yr CAGR Net Profit	n/a	14.26 %	-64.03 %
5yr Average Return on Assets	0.71 %	11.52 %	6.95 %
Shareholdings
Promoter Holding	52.61 %	72.51 %	72.48 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-0.41 %	-2.97 %	-1.11 %
Change in Mutual Fund Holding (3 Yrs)	9.92 %	2.36 %	0.0

Business

	Sequent Scientific	Gufic Biosciences	Panacea Biotec
Segment Break-Up	Segment Break-Up Production animal 81.0 Companion animal 19.0 Both 0	-	-
Segment Break-Up	Segment Break-Up Production animal 81.0 Companion animal 19.0 Both 0	-	-
Product Wise Break-Up	Product Wise Break-Up Formulations 78.27 Active Pharmaceutical Ingredient (API) 21.13 API 0 Muscle Relaxants 0 Cardiovascular 0 Proton pump inhibitors 0 Anti-fungals 0 Anti-bacterials 0 International 0 CMO 0 Domestic 0 Research and Development 0 Vaccines 0 Others 0.6	Product Wise Break-Up Cardiovascular 0 Muscle Relaxants 0 Anti-bacterials 0 Formulations 0 International 15.0 Active Pharmaceutical Ingredient (API) 5.0 Research and Development 0 Vaccines 0 Domestic Pharmaceuticals 50.0 Anti-fungals 0 Active Pharmaceutical Ingredient (API) 0 Proton pump inhibitors 0 CMO 30.0	Product Wise Break-Up Cardiovascular 0 Muscle Relaxants 0 Anti-bacterials 0 Formulations 33.67 International 0 API 0 Research and Development 0 Vaccines 66.33 Domestic 0 Anti-fungals 0 Active Pharmaceutical Ingredient (API) 0 Proton pump inhibitors 0 CMO 0
Location Wise Break-Up	Location Wise Break-Up Europe 41.73 Rest of the World 34.17 Asia Pacific 24.1 Turkey 0 LATAM 0 EM 0 South America 0 Australia 0 North America 0 Africa 0 India 0	Location Wise Break-Up Europe 3.67 Turkey 0 EM 0 Australia 0.53 North America 1.27 India 89.07 Asia Pacific 0 Africa 0.72 South America 0.23 Rest of the World 0 LATAM 0 Others 4.51	Location Wise Break-Up Europe 0 Turkey 0 EM 0 Australia 0 North America 0 India 13.91 Asia Pacific 0 Africa 0 South America 0 Rest of the World 86.09 LATAM 0
Customer Segment	Customer Segment Regulated market 67.0 Less regulated market 33.0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Antibiotic Injectables 33.0 Antibiotic Non-Injectables 15.0 Anthelmintics 11.0 Nutritional 0 Pain management 0 Others 41.0	-	-
R&D Break-Up - Product Wise	R&D Break-Up - Product Wise Formulations 40.0 NiCad 29.0 Patent expiry opportunity 18.0 First generic 9.0 Incremental innovation 4.0	-	-
Dosage Form Break-Up	Dosage Form Break-Up Injectable 55.0 Powder/Premixes 26.0 Solid 6.0 Paste and others 0 Pour on/Spot on 0 Oral Solutions/Suspensions 0 Others 13.0	-	-
Asset Break-Up	Asset Break-Up Asia Pacific 51.03 Europe 24.72 Rest of the World 24.25 Real Estate 0 Formulations 0 Vaccines 0	-	Asset Break-Up Europe 0 Formulations 34.72 Vaccines 65.28 Asia Pacific 0 Rest of the World 0 Real Estate 0
Species Break-Up	Species Break-Up Multispecies 39.0 Ruminants 32.0 Poultry And Poultry Products 12.0 Companion 10.0 Swine 6.0 Others 1.0	-	-

Sequent Scientific Ltd.

SIGN UP FOR FREE